Update (June 9, 2026): FDA ADAE Disproportionality Analysis Identifies 19 Frunevetmab AE Signals in Cats

TL;DR. A January 2026 disproportionality analysis of the FDA ADAE database identified 19 significant adverse event signals for frunevetmab in cats, including skin-related events expected from the label and several unexpected signals (abnormal cytology, arthritis, paresis) absent from the package insert.

What just dropped

Lai X, Lin L, Chen Y, Wu L, Huang Y, and Chen M published "Safety assessment of frunevetmab for osteoarthritis pain in cats: disproportionality analysis of the Food and Drug Administration Animal Drug Adverse Events database" in the Journal of Veterinary Internal Medicine (January 2026; PMID 41742572; PMC12893208; DOI 10.1093/jvimsj/aalag003). The study analyzed 5,248 frunevetmab-specific adverse event reports from 33,378 total feline AE reports in the FDA ADAE database (January 2022 through December 2024). Four complementary disproportionality metrics were applied: reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS).

Context

Frunevetmab (Solensia, Zoetis) is a felinized monoclonal antibody targeting nerve growth factor (NGF), approved for management of osteoarthritis pain in cats. It is injected subcutaneously monthly. As an anti-NGF biologic, its known adverse event profile includes injection-site reactions and skin changes. Post-marketing safety surveillance is important for biologics in new species, as controlled trial populations may not capture rare events or events in cats with concurrent comorbidities.

What this changes in frunevetmab-solensia-feline-osteoarthritis (https://www.thevoyage.ai/forvets/knowledge/frunevetmab-solensia-feline-osteoarthritis)

The frunevetmab evergreen page covers the pivotal trial efficacy evidence. Lai et al. 2026 adds the most comprehensive real-world safety analysis to date:

Significant AE signals identified (all require clinical confirmation - these are hypothesis-generating pharmacovigilance findings):

• Most frequently reported: pruritus, unspecified skin disorders, alopecia, dermatitis and eczema, unspecified skin lesions
• Highest signal strength (ROR/PRR/BCPNN/MGPS): skin ulceration, unspecified skin disorders, unspecified skin lesions, injection site pain, dermatitis and eczema
• Unexpected signals absent from the package insert: abnormal cytology, arthritis, paresis

The authors emphasize that disproportionality analysis generates hypotheses and does not establish causation. Reporting bias, confounding by indication (cats with OA may have concurrent diseases), and incomplete report data are important limitations. However, the paresis signal is notable given that anti-NGF antibodies in other species have been associated with effects on peripheral nerve function, and this warrants monitoring in clinical practice.

Clinical recommendation from the authors: veterinarians should implement robust clinical monitoring for skin changes and monitor for neurological signs in frunevetmab-treated cats. Reporting of adverse events to the FDA ADAE database supports ongoing pharmacovigilance.

References

1. Lai X, Lin L, Chen Y, et al. Safety assessment of frunevetmab for osteoarthritis pain in cats: disproportionality analysis of the Food and Drug Administration Animal Drug Adverse Events database. J Vet Intern Med. 2026;40(1):aalag003. https://pubmed.ncbi.nlm.nih.gov/41742572/

Voyage Clinical Desk

From clinical question to SOAP draft - cited differentials, live dose calculators, owner handouts. Trained on the veterinary canon (Plumb's, Ettinger, JVIM, ACVIM consensus, 50,000+ indexed references). First answer free, no signup.

Open Voyage Clinical Desk: https://www.thevoyage.ai/forvets/ask?context=frunevetmab-solensia-feline-osteoarthritis

Changelog

• 2026-06-09: First published.

Related reads

• Frunevetmab (Solensia) for Feline Osteoarthritis: Effectiveness and Real-World Safety